You are here

Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

Last updated on June 6, 2019

FOR MORE INFORMATION
Study Location
UC Irvine Medical Center
Orange, California, 92868 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Solid Tumors
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-99 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients who were assigned to an axitinib (AG-013736) containing treatment arm in a
previous clinical trial

- Patients who were receiving axitinib (AG-013736) tablets at the time their previous
trial ended

- Patients who have stable (SD) or responding disease (PR or CR) documented by the
appropriate radiological, clinical, or laboratory assessments within 12 weeks before
enrollment (Note: response criteria from the previous axitinib (AG-013736) protocol
should be used to determine stable or responding disease).

- Patients who have progressive disease (PD) but have experienced "clinical benefit" as
defined in the study protocol

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients may not participate in this trial if the conditions for continuing treatment
in the previous axitinib (AG-013736) protocol are not met

NCT00828919
Pfizer
Active, not recruiting
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
NCT03330405
All Genders
18+
Years
Multiple Sites
Locally Advanced or Metastatic Solid Tumors, BRCA 1 Genes
NCT03565991
All Genders
18+
Years
Multiple Sites
Solid Tumors, Ewing Sarcoma, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma
NCT03709680
All Genders
2+
Years
Multiple Sites
Advanced Solid Tumors, Metastatic Solid Tumors
NCT03854227
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now